Twist Bioscience rises on licensing deal for antibody discovery platform
Source: SeekingAlpha
2026-02-17 12:05:40 ET
More on Twist Bioscience
- Twist Bioscience: Liquid Biopsy And AI Tailwinds
- Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases
- Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript
- Twist Bioscience outlines $435M–$440M 2026 revenue target while accelerating AI-enabled discovery investments
- Twist Bioscience rises as fiscal 2026 revenue guidance raised
Read the full article on Seeking Alpha
For further details see:
Twist Bioscience rises on licensing deal for antibody discovery platform
Twist Bioscience Corporation
NASDAQ: TWST
TWST Trading
3.33% G/L:
$51.77 Last:
482,262 Volume:
$53.04 Open:
TWST Latest News
April 08, 2026 03:56:43 am
Twist Bioscience Corporation (NASDAQ:TWST) Receives $46.50 Consensus Target Price from Analysts
February 17, 2026 07:00:00 am
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
TWST Stock Data
$2,986,186,543
59,423,304
2.85%
91
N/A
Medical Diagnostics & Screening
Healthcare
US
South San Francisco
